Society

Biognosys and Alamar Biosciences Forge Strategic Partnership in Proteomics to Advance Biopharma and Precision Medicine Research

Retrieved on: 
Thursday, April 4, 2024
Plasma, NSCLC, Disease, Partnership, Inflammation, Patient, Biomarker, Research, Acquisition, Protein, Proteomics, Biology, Medicine, AACR, Chemokine, Society, Cytokine, Mass spectrometry, Fluid mechanics, Proteome, Annual general meeting, Pharmaceutical industry

This collaboration brings together Biognosys’ expertise in unbiased discovery through data independent acquisition mass spectrometry (DIA-MS) and Alamar’s cutting-edge immunoassays.

Key Points: 
  • This collaboration brings together Biognosys’ expertise in unbiased discovery through data independent acquisition mass spectrometry (DIA-MS) and Alamar’s cutting-edge immunoassays.
  • Building upon this successful proof-of-concept study, Biognosys and Alamar are planning to further collaborate both commercially and scientifically as part of their strategic partnership.
  • Research Collaboration: Biognosys and Alamar will embark on a joint research initiative to explore plasma biology.
  • Oliver Rinner, Ph.D., Founder and CEO of Biognosys, expressed enthusiasm about the collaboration: “We are excited to join forces with Alamar to advance proteomics research.

MacroGenics Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures

Retrieved on: 
Wednesday, April 3, 2024
Docetaxel, Prostate cancer, ECOG, B7-H3, Patient, Cancer, Autumn, Society, Safety, ASCO, Therapy, PFS, ADC, Annual general meeting, Pharmaceutical industry

As previously disclosed, safety data from the Company’s ongoing TAMARACK Phase 2 study was submitted in early February to the American Society of Clinical Oncology (ASCO) for presentation at the upcoming Annual Meeting that begins May 31.

Key Points: 
  • As previously disclosed, safety data from the Company’s ongoing TAMARACK Phase 2 study was submitted in early February to the American Society of Clinical Oncology (ASCO) for presentation at the upcoming Annual Meeting that begins May 31.
  • The abstract containing this early interim data, based on a January 4, 2024 data cut-off, was not accepted.
  • TAMARACK is an ongoing randomized, open-label, Phase 2 dose selection study assessing the efficacy, safety, and tolerability of two dose levels of vobra duo (2.0 mg/kg and 2.7 mg/kg IV Q4W).
  • At data cutoff (Jan 4, 2024), 182 pts with mCRPC enrolled on TAMARACK, of which 177 received vobra duo.

Eyenovia to Feature its Suite of Commercial Products and the Optejet Dispenser at Upcoming National Eyecare Meetings

Retrieved on: 
Wednesday, April 3, 2024
Clobetasol, Exchange, Infection, Acceleration, Refractive surgery, Inflammation, Annual general meeting, ASCRS, Patient, Private practice, Cataract, Society, Ophthalmology

NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic company, today announced that the company will be conducting demonstrations of its portfolio of commercial products at two upcoming ophthalmology medical meetings.

Key Points: 
  • “Our presence at national medical and commercial meetings like these are key to elevating awareness of our continuum of office-based and surgical products,” stated Michael Rowe, Eyenovia’s Chief Executive Officer.
  • These meetings complement the efforts of our field sales force in amplifying the synergistic nature of our product portfolio as well as the many benefits conferred to doctors and patients by the Optejet device.
  • Eyenovia will also be demonstrating Avenova and reviewing now-approved data on clobetasol, which complements the company’s surgical suite of products.
  • The event features continuing education, keynote speakers, Exchange-only pricing from more than 100 vendors, and opportunities to network with colleagues.

FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer

Retrieved on: 
Tuesday, April 2, 2024
Neutropenia, Prostate cancer, Survival, RECIST, Prostate-specific antigen, Patient, SAN, Neoplasm, MMAE, Weight loss, Publishing, Peripheral neuropathy, University, CD46, Spacecraft, Society, Safety, ASCO, Adenocarcinoma, Fatigue, ADC, PSA, FDA, Fortis, Lead, Food, Pharmaceutical industry

“We are delighted to showcase the latest encouraging clinical data from the FOR46-001 Phase 1 ADC trial,” said Deyaa Adib, M.D., Chief Medical Officer of FibroGen.

Key Points: 
  • “We are delighted to showcase the latest encouraging clinical data from the FOR46-001 Phase 1 ADC trial,” said Deyaa Adib, M.D., Chief Medical Officer of FibroGen.
  • In the dose-expansion arm of the trial, patients were treated at the 2.7 mg/kg adjusted body weight dosing (AjBW) until disease progression.
  • The completed Phase 1 trial includes a total of 56 patients from the dose-escalation and dose-expansion cohorts.
  • These findings warrant further investigation and hold promise for addressing the therapeutic needs of patients with CD46 positive prostate cancer.

ASSP takes position opposing exploitative child labor

Retrieved on: 
Tuesday, April 2, 2024
Health, Learning, Environment, United, ASSP, ESG, United Nations, Child, Society, International Labour Organization, Workforce, CIH, Injury, Language, CSP, ANSI, Fatality, Toy

The statement from the board of directors declares that ASSP opposes all forms of exploitative child labor and calls on governmental and nongovernmental entities to combat such practices in the U.S. and worldwide.

Key Points: 
  • The statement from the board of directors declares that ASSP opposes all forms of exploitative child labor and calls on governmental and nongovernmental entities to combat such practices in the U.S. and worldwide.
  • “There has been a focus to loosen U.S. child labor laws to help industry combat labor shortages,” Thornton said.
  • With its child labor position set, ASSP will now pursue next steps that include:
    Publishing articles and hosting webinars to educate the occupational safety and health community.
  • Working with other occupational safety and health organizations to help prohibit exploitative child labor.

MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)

Retrieved on: 
Wednesday, April 3, 2024
Harvard Medical School, Dana–Farber Cancer Institute, GBM, Code, Glioblastoma, Clinical trial, Society, Brigham and Women's Hospital, Hospital, Tokyo Stock Exchange, ASCO, Neuro-Oncology (journal), Annual general meeting

LA JOLLA, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding results of a clinical trial of MN-166 (ibudilast) in glioblastoma (GBM) has been selected for an oral presentation at the American Society of Clinical Oncology (2024 ASCO) Annual Meeting to be held May 31 – June 4, 2024 in Chicago.

Key Points: 
  • LA JOLLA, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding results of a clinical trial of MN-166 (ibudilast) in glioblastoma (GBM) has been selected for an oral presentation at the American Society of Clinical Oncology (2024 ASCO) Annual Meeting to be held May 31 – June 4, 2024 in Chicago.
  • The oral presentation will be presented by one of the investigators of this clinical trial, Gilbert Youssef, M.D., Attending Physician at Harvard Medical School, Center for Neuro-Oncology at Dana-Farber Cancer Institute and Brigham and Women's Hospital.
  • The presentation details are as follows:

EXP expands expertise with dedicated Transportation Sector in Central Canada

Retrieved on: 
Tuesday, April 2, 2024
EXP, Professional Engineers Ontario, University, Transport, Toronto Metropolitan University, Majdi, ASCE, Electrification, RER, Society, BRT, Architecture, Alexandria University, AVS, SAVE, Ministry, Rehabilitation

BRAMPTON, Ontario, April 02, 2024 (GLOBE NEWSWIRE) -- EXP, a global engineering, architecture, design and consulting firm, has announced the establishment of a new Central Canada Transportation Sector, celebrating an expansion of its Central Canada Infrastructure practice.

Key Points: 
  • BRAMPTON, Ontario, April 02, 2024 (GLOBE NEWSWIRE) -- EXP, a global engineering, architecture, design and consulting firm, has announced the establishment of a new Central Canada Transportation Sector, celebrating an expansion of its Central Canada Infrastructure practice.
  • P.Eng., PE, AVS, will prioritize expanding EXP’s position within the transportation industry, pinpointing strategic growth avenues and enhancing transportation outcomes for municipalities and provinces in Central Canada.
  • Magdy joined EXP in 2020 as Vice President, Transportation Central Canada in EXP’s Central Canada Infrastructure practice.
  • He has been responsible for bolstering EXP’s transportation practice and supporting EXP teams in firm-wide transportation pursuits.

OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery

Retrieved on: 
Tuesday, April 2, 2024
NCP, Refractive surgery, ASCRS, Cataract, DED, Society, Pain, Telecanthus, FDA, Annual general meeting

LONDON and NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, today announced an upcoming presentation of the OK-101 Phase 2 data for dry eye disease at Eyecelerator 2024, a partner meeting of the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, being held April 4, 2024 in Boston, MA.

Key Points: 
  • LONDON and NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, today announced an upcoming presentation of the OK-101 Phase 2 data for dry eye disease at Eyecelerator 2024, a partner meeting of the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, being held April 4, 2024 in Boston, MA.

SpyGlass Pharma Unveils Compelling 1-Year Data of Its Innovative Drug Delivery Platform Implanted During Routine Cataract Surgery in Eyes with Glaucoma

Retrieved on: 
Tuesday, April 2, 2024
IOP, Bimatoprost, Glaucoma, Ocular hypertension, Pressure, IOL, ASCRS, Patient, Tissue, Cataract, Month, Spyglass, Visual acuity, Society, Safety, IOPS, Therapy, FDA, Intraocular pressure, Annual general meeting, Pharmaceutical industry

ALISO VIEJO, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately-held ophthalmic biotechnology company, announced today 1-year follow up data from a first-in-human study of 23 patients with glaucoma or ocular hypertension implanted with SpyGlass’ Intraocular Lens (IOL) based Drug Delivery Platform with bimatoprost at the time of cataract surgery. These data will be highlighted in a poster presentation during the American Society of Cataract and Refractive Surgeons (ASCRS) Annual Meeting, held from April 5-8 in Boston.

Key Points: 
  • ALISO VIEJO, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately-held ophthalmic biotechnology company, announced today 1-year follow up data from a first-in-human study of 23 patients with glaucoma or ocular hypertension implanted with SpyGlass’ Intraocular Lens (IOL) based Drug Delivery Platform with bimatoprost at the time of cataract surgery.
  • The SpyGlass platform was well tolerated and there were no adverse events related to the product.
  • These data highlight the substantial potential of the SpyGlass Drug Delivery Platform to be a game changer for patients and all cataract surgeons.”
    “SpyGlass technology has the potential to change the paradigm and improve care for glaucoma patients undergoing routine cataract surgery,” said Patrick Mooney, CEO, SpyGlass PharmaTM.
  • The compelling clinical data released this week suggest we are on track to bringing our innovative platform to patients.”
    The SpyGlass Drug Delivery Platform with bimatoprost is designed to deliver 3 years of bimatoprost to targeted tissues.

APA Corporation Appoints Matthew Bob and Anya Weaving to Board of Directors

Retrieved on: 
Monday, April 1, 2024
Unocal Corporation, Head, Primary energy, Renaissance Capital, APA Corporation, UBS, Bank, Society, Pharos Energy, BofA Securities, APA, Management

HOUSTON, April 01, 2024 (GLOBE NEWSWIRE) -- APA Corporation (Nasdaq: APA) today announced the appointment of Matthew Bob and Anya Weaving to its board of directors.

Key Points: 
  • HOUSTON, April 01, 2024 (GLOBE NEWSWIRE) -- APA Corporation (Nasdaq: APA) today announced the appointment of Matthew Bob and Anya Weaving to its board of directors.
  • “We are very pleased to welcome Matthew and Anya to the APA board,” said Lamar McKay, APA’s nonexecutive board chair.
  • “Matthew brings extensive executive and operational experience with U.S. onshore oil and gas companies in addition to his technical expertise.
  • His knowledge of Callon will provide the board with valuable insight and guidance on the newly acquired company assets.